Clot Formation in Cardiopulmonary Bypass Circuit After Application of Factor XI Concentrate

Hulsman, Niels; Meulen, Jan van der; Talacua, Hanna; Essoussi, Bachir; Hermanns, Henning

doi:10.1053/j.jvca.2020.02.013

Search citation statements

Order By: Relevance

Paper Sections

Select...

The Uses Of Clotting Factor Concentrate In Hematologic Disea2

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2020

2022

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

(2 citation statements)

References 10 publications

(11 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A plasma-derived concentrate has existed for over 2 decades now with a good safety profile for its limited patient population [141] . Expansion of extracorporeal life support system usage has demonstrated that Factor XI concentrate exacerbates the already prevalent clot formation in the bypass circuit [142] .…”

Section: The Uses Of Clotting Factor Concentrate In Hematologic Diseamentioning

confidence: 99%

See 1 more Smart Citation

Recent advances in use of fresh frozen plasma, cryoprecipitate, immunoglobulins, and clotting factors for transfusion support in patients with hematologic disease

Nair

Rendo

Reddoch-Cardenas

et al. 2020

Seminars in Hematology

View full text Add to dashboard Cite

Hematologic diseases include a broad range of acquired and congenital disorders, many of which affect plasma proteins that control hemostasis and immune responses. Therapeutic interventions for these disorders include transfusion of plasma, cryoprecipitate, immunoglobulins, or convalescent plasma-containing therapeutic antibodies from patients recovering from infectious diseases, as well as concentrated pro- or anticoagulant factors. This review will focus on recent advances in the uses of plasma and its derivatives for patients with acquired and congenital hematologic disorders.

show abstract

Section: The Uses Of Clotting Factor Concentrate In Hematologic Diseamentioning

confidence: 99%

“…Factor XII deficiencies are rare and have little impact on the patient [142] . No treatments are necessary.…”

Section: The Uses Of Clotting Factor Concentrate In Hematologic Diseamentioning

confidence: 99%

Recent advances in use of fresh frozen plasma, cryoprecipitate, immunoglobulins, and clotting factors for transfusion support in patients with hematologic disease

Nair

Rendo

Reddoch-Cardenas

et al. 2020

Seminars in Hematology

View full text Add to dashboard Cite

show abstract

Factor-XI

2020

Reactions Weekly

View full text Add to dashboard Cite

Cardiopulmonary Bypass Emergencies and Intraoperative Issues

Gerstein

Panikkath

Mirrakhimov

et al. 2022

Journal of Cardiothoracic and Vascular Anesthesia

View full text Add to dashboard Cite

Clot Formation in Cardiopulmonary Bypass Circuit After Application of Factor XI Concentrate

Cited by 3 publications

References 10 publications

Recent advances in use of fresh frozen plasma, cryoprecipitate, immunoglobulins, and clotting factors for transfusion support in patients with hematologic disease

Recent advances in use of fresh frozen plasma, cryoprecipitate, immunoglobulins, and clotting factors for transfusion support in patients with hematologic disease

Factor-XI

Cardiopulmonary Bypass Emergencies and Intraoperative Issues

Contact Info

Product

Resources

About